Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mebrofenin is a synthetic iminodiacetic acid (IDA) derivative used as a chelating agent for the radiopharmaceutical technetium Tc 99m. The resulting compound, technetium Tc 99m mebrofenin, is a diagnostic radiopharmaceutical administered intravenously to evaluate hepatobiliary function. After injection, it is rapidly taken up by hepatocytes in the liver and excreted into the bile ducts and gallbladder. Its mechanism relies on high hepatic extraction efficiency and fast biliary excretion, enabling imaging of the liver, gallbladder, and bile ducts using gamma cameras that detect gamma rays emitted by technetium-99m decay. Mebrofenin uptake occurs via Organic Anion Transporting Polypeptide 1B1 (OATP1B1) and Organic Anion Transporting Polypeptide 1B3 (OATP1B3) transporters in hepatocytes; excretion into bile canaliculi involves Multidrug Resistance-Associated Protein 2 (MRP2). It has no known pharmacologic action at recommended doses but serves as an essential tool for non-invasive assessment of liver function and biliary patency[1][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mebrofenin.